CD8A and neoplasm: TAS-115 is expected to exhibit both anti-angiogenesis activity and increase the percentage of active T cell populations, Gzmb+CD8+ T cells, IFNγ+CD8+ T cells, and MuLV+CD8+ T cells, relative to CD8+ T cells in tumor.